CN111479828B - 抗糖-muc1抗体及其用途 - Google Patents

抗糖-muc1抗体及其用途 Download PDF

Info

Publication number
CN111479828B
CN111479828B CN201780097773.8A CN201780097773A CN111479828B CN 111479828 B CN111479828 B CN 111479828B CN 201780097773 A CN201780097773 A CN 201780097773A CN 111479828 B CN111479828 B CN 111479828B
Authority
CN
China
Prior art keywords
antibody
seq
muc
saccharide
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780097773.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111479828A (zh
Inventor
T.怀特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Go Medical Co ltd
Original Assignee
Go Medical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Go Medical Co ltd filed Critical Go Medical Co ltd
Publication of CN111479828A publication Critical patent/CN111479828A/zh
Application granted granted Critical
Publication of CN111479828B publication Critical patent/CN111479828B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4725—Mucins, e.g. human intestinal mucin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201780097773.8A 2017-10-24 2017-10-24 抗糖-muc1抗体及其用途 Active CN111479828B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2017/058036 WO2019083506A1 (en) 2017-10-24 2017-10-24 ANTI-GLYCO-MUC1 ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
CN111479828A CN111479828A (zh) 2020-07-31
CN111479828B true CN111479828B (zh) 2024-07-05

Family

ID=66247577

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780097773.8A Active CN111479828B (zh) 2017-10-24 2017-10-24 抗糖-muc1抗体及其用途

Country Status (10)

Country Link
EP (1) EP3700936A4 (cg-RX-API-DMAC7.html)
JP (2) JP7358367B2 (cg-RX-API-DMAC7.html)
KR (2) KR102608763B1 (cg-RX-API-DMAC7.html)
CN (1) CN111479828B (cg-RX-API-DMAC7.html)
AU (1) AU2017436815B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008001A2 (cg-RX-API-DMAC7.html)
CA (1) CA3078812A1 (cg-RX-API-DMAC7.html)
IL (1) IL274202A (cg-RX-API-DMAC7.html)
MX (1) MX2020004220A (cg-RX-API-DMAC7.html)
WO (1) WO2019083506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.
EP4188432A4 (en) * 2020-07-31 2024-08-21 R.P. Scherer Technologies, LLC ANTIBODY SPECIFIC FOR MUCIN-1 AND METHODS OF USE THEREOF
AU2022333837A1 (en) * 2021-08-27 2024-03-14 Peptron, Inc. Novel anti-muc1 antibody and use thereof
AU2022420709A1 (en) * 2021-12-21 2024-08-01 Merus N.V. Binding domains against cancer-associated muc1
CN114099685B (zh) * 2022-01-27 2022-06-21 中国农业大学 抑制muc1表达和糖基化修饰的物质在降低抗乳腺癌药物耐药性中的应用
AU2024251169A1 (en) * 2023-04-13 2025-10-23 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen binding molecule specifically binding to egfr and muc1, drug conjugate thereof, and medical use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020146750A1 (en) * 2000-03-30 2002-10-10 Hoogenboom Hendricus R.J.M. Mucin-1 specific binding members and methods of use thereof
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2008040362A2 (en) * 2006-10-04 2008-04-10 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
EP2014302A1 (en) * 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
CN101978054B (zh) * 2007-12-05 2013-05-29 协和发酵麒麟株式会社 能够与肝素结合性表皮生长因子样生长因子结合的单克隆抗体
EP2351777B1 (en) * 2008-10-28 2015-10-28 Shionogi&Co., Ltd. Anti-muc1 antibody
EP2281844A1 (en) * 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
WO2015120180A1 (en) * 2014-02-05 2015-08-13 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific tn glycopeptide variants
EP3150634B1 (en) * 2014-04-28 2020-04-22 Medicinal Chemistry Pharmaceuticals Co., Ltd. Anti-muc1 antibody or antigen-binding fragment thereof, and uses thereof
BR112020008001A2 (pt) * 2017-10-24 2020-10-20 Go Therapeutics, Inc. anticorpo anti-glico-muc1 ou fragmento de ligação de antígeno, proteína de fusão, receptor de antígeno quimérico, conjugado de anticorpo-fármaco, ácido nucleico, vetor, célula hospedeira, composição farmacêutica, e, métodos de tratar câncer e de detectar câncer em uma amostra biológica.

Also Published As

Publication number Publication date
CA3078812A1 (en) 2019-05-02
MX2020004220A (es) 2020-10-05
KR20200067885A (ko) 2020-06-12
KR102832078B1 (ko) 2025-07-08
AU2017436815A1 (en) 2020-04-23
IL274202A (en) 2020-06-30
BR112020008001A2 (pt) 2020-10-20
AU2017436815B2 (en) 2025-05-29
JP2024001073A (ja) 2024-01-09
KR20230165874A (ko) 2023-12-05
CN111479828A (zh) 2020-07-31
KR102608763B1 (ko) 2023-11-30
JP7358367B2 (ja) 2023-10-10
EP3700936A1 (en) 2020-09-02
JP2021510307A (ja) 2021-04-22
EP3700936A4 (en) 2021-05-26
WO2019083506A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
US12065504B2 (en) Anti-glyco-MUC1 antibodies and their uses
US20230126689A1 (en) Anti-glyco-cd44 antibodies and their uses
CN111479828B (zh) 抗糖-muc1抗体及其用途
US20250304716A1 (en) Anti-glyco-muc1 antibodies and their uses
US20250136701A1 (en) Anti-glyco-cmet antibodies and their uses
US20250066498A1 (en) Anti-glyco-lamp1 antibodies and their uses
US20250101126A1 (en) Anti-glyco-muc4 antibodies and their uses
JP2024512324A (ja) 抗グリコｃｄ４４抗体およびその使用
CN118354788A (zh) 抗糖-muc4抗体及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TG01 Patent term adjustment
TG01 Patent term adjustment